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Pentadecylcatechol (PDC) (1 mg) incorporated into 
liposomes (PDC-liposomes) and given by intracardiac 
injection to guinea pigs 1 week prior to attempted topical 
sensitization to PDC significantly inhibited that sensiti-
zation as evidenced by patch tests done 2 weeks after the 
attempted topical sensitization. PDC (1 mg) dissolved in 
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ethanol did not significantly inhibit sensitization. Sensi-
tization inhibition was specific since dinitrochloroben-
zene sensitization was not inhibited by prior intracar-
diac treatment with PDC-liposomes. In addition, the sen-
sitization to PDC was no longer inhibited if the time 
between the intracardiac PDC-liposome injection and 
Abbreviations: 
DNBSO:~ : dinitrobenzenesulphonate 
DNCB: 1-chloro-2,4-dinitrobenzene 
DNFB: 1-0uoro-2,4-dinitrobenzene 
EGME: ethylene glycol monomethyl ether 
i.e.: in tracardiac 
i.d.: in tradermal 
PDC: 3-n-pentadecylcatechol 
RES: reticuloendothelia l system 
146 COLBY, ARTIS, AND RIETSCHEL 
the topical PDC sensitizing dose was increased from 1 
week to 2 or more weeks. 
Allergic contact dermatitis to toxicodendron (poison ivy, oak, 
sumac) is a major cause of morbidity in the United States. 
Sensitization leading to toxicodendron allergic contact derma-
titis and other contact allergies is favored by antigen entering 
through the skin. Other routes of presentation such as oral or 
mucosal, intravenous (i.v.), and subcutaneous may produce 
hyposensitization or immune tolerance to antigens that are 
contact sensitizers [1-3). S ince Sulzberger's work with neo-
arsphenamine, i.v. administration has been the best route for 
inducing tolerance to a contact allergen [ 4). 
Allergic contact dermatitis to the toxicodendron antigen, 3-
n-pentadecylcatechol (PDC), has been partially prevented by 
oral feeding and subcuta neous or i.m. injection in oil [1,2,5,9]. 
Because PDC is a crystalline wax at body temperature, i.v. 
administration without chemical alteration or emulsification 
has not been feasible [6). 
Liposomes are microscopic phospholipid vesicles into which 
lipid-soluble substances like PDC can be incorporated. Lipo-
somes can be injected i.v. because they can be made to a small 
particle size(::::: 4 p,m). When injected i.v., liposomes are cleared 
from the circulation by the reticuloendothelial system (RES) 
largely by phagocytosis but also by fusion with cell m embranes 
of the RES [7 -11]. Because of these features, liposomes may be 
a useful vehicle for inducing tolerance to PDC not only by 
facilitating the introduction of the allergen into the vascular 
system but also by promoting antigen interaction with cell 
membranes of the RES that are responsible for a ntigen proc-
essing and presentation. · 
T he purpose of our investigation was to determine whether 
the injection of liposom es containing PDC into the vascular 
system of guinea pigs is capable of inhibiting topical sensitiza-
t ion to PDC. 
MATERIALS AND METHODS 
Animals 
Female Hartley strain guinea pigs weighing 450-600 g were pur-
chased from Elm Hill Breeding Laboratories, Chelmsford , Massachu-
setts. They were fed P urina guinea pig chow and water ad lib in a 
controlled environment. 
Antigens 
l -Chloro-2,4-dinitrobenzene (DNCB) was obtained from Aldrich 
Chemical Company, Inc., Milwaukee, Wisconsin. 
3-n-PDC was synthesized and characterized by Dr. P eter Kurtz, 
Letterman Army Institu te for Research , San Francisco, California. 
Chemicals 
L-t~·phosphatidy lcholine (phosphatidyl choline) prepared from egg 
yolk and found to be 60% pure, 5-cholesten-3-ol (Cholesterol) 90+% 
pure, and dicetyl phosphate were obtained from Sigma Chemical Corp., 
St. Louis, Missouri . Methanol and ethylene glycol monomethyl ether 
(EGME) were obtained from Fisher Scientific, F airlawn, New J ersey. 
Chloroform was obtained fro m Mallinckrodt, Inc., St. Louis, Missouri. 
Liposomes 
Liposomes were prep~red by standard techniques [7,8,11] by com7 
bining phosphatidylcholine, cholesterol, a nd dicetyl phosphate both 
with PDC (PDC-liposomes) and without PDC (empty liposomes) in 
molar ratios of 7:1:1:1. The lipids were dissolved in 25 cc of chloroform 
and methanol (5:1) which was then evaporated using a roto evaporato r 
(Servo Instrument) to leave a lipid·fLlrn on the inside of a 125-ml round-
bottom fl ask. Ten milliliters of phosphate-buffered saline (pH 7.2, 0.15 
M) was then added, and the flask was hand shaken to produce large 
multilamellar liposomes. Small liposomes less than 7 11m in size were 
produced by sonication for 1 min using a Branson Sonifier, Model 185, 
operated at level 3-5. The suspension was centri fuged at 1500 g for 15 
min at 4°C to remove any lipids not incorporated into the liposome 
suspension. For i11tracardiac (i. e. ) injection, 1.0 mg of PDC in the form 
of PDC- Iiposomes was given per animal, per injection (1-2 cc tota l 
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volume). For in tradermal (i.d.) inj ections, PDC-liposomes containing 
0.1-0.16 mg PDC were injected. 
Sen.;;itization and Elicitation 
Guinea pigs were shaved and epilated with M agic S have (Carson 
Products, Savannah , Georgia) prior to sensit ization and patch testing. 
Sensitization was accomplished by applying 250 lig of PDC dissolved in 
50 111 of EGME to a 5-cm diameter circular area between the shoulder 
blades. DNCB sensitization was accomplished by applying 2000 JI.g 
DNCB in 50 ~tl EGME to a 5-cm diameter circular area also located 
between the shoulder blades. 
E licitation patch tests were done using serial dilutions of PDC 
prepared in 20 ~tl of EGME as follows: 50, 25, 12.5, 6.25, 3.13, 1.57, and 
0.79 lig per patch applied to the shaved and epilated flank skin. The 
circular a reas for patch testing were each 1 em in diameter. DNCB 
patches wer e done using 100, 75, 50, 40, 30, 25, 20, and 10 lig of DNCB 
dissolved in 20 ~tl EGME applied over a circular a rea 1 em in diameter. 
Patch tests using PDC-Iiposomes and empty liposomes were done 
using 20 ~tl of PDC-liposomes (5-8 lig PDC) or 20 ~tl empty liposomes 
applied over a 1-cm diameter circulru· area on shaved and epilated 
guinea pig backs. Pa tch tests were read at 48 and 72 h by one experi-
menter and one nonpartia l observer. All patches showing vis ible ery-
thema were recorded as a positive patch test. 
Statistical analysis using the Wilcoxon Sum Rank T est was used to 
compru·e groups of animals. A p value of < 0.005 was considered to 
show a highly s igniticant difference. A p value of> 0.05 was considered 
to no t show any significant difference. 
RESULTS 
The first experiment was designed to distinguish an allergic 
contact dermatitis from an irritant contact dermatitis produced 
by PDC and DNCB for the various patch test concentrations. 
Fig 1 shows that 2::95% of naive animals (no prior exposure to 
allergen tested) develop a dermatitis to PDC at concentrations 
2::12.5 p,g. Two weeks after sensitization with 250 p,g of PDC, 
92% of sensitized animals reacted to 6.25 p,g PDC and 55% to 
3.13 p,g PDC. Less than 20% of the sensitized animals reacted to 
1.57 p,g PDC. This experiment indicates that a positive patch 
test at :::::6.25 p,g PDC represents an allergic contact dermatitis 
while a positive patch at ::::12.5 p,g is an irritant contact derma-
titis. 
S imilarly, Fig 2 shows that sensitization with 2000 p,g DNCB 
2 weeks prior to patch testing induced positive patches at 
concentratio ns of DNCB 2::20 p,g DNCB. Naive animals devel-
oped positive patches only at concentrations of ::::50 p,g. Thus a 
positive reaction at :::::40 p,g DNCB represents allergic contact 
dermatit is whereas a reaction at >50 p,g of DNCB indicates a n 
irritant contact dermatitis. 
To determine whether liposomes containing PDC retain the 
capacity to elicit contact dermatitis, naive and sensitized guinea 
pigs were patch tested with PDC-liposomes (5-10 p,g PDC) and 
empty liposomes (no PDC) (data not shown). At 24, 48, and 72 
h , naive a nimals showed no erythema to either PDC-liposome 
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FIG l. Cutaneous reactivity of na ive vs. PDC-sensitized guinea pigs 
to PDC patch tests. 
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patches or to empty liposome patches. A moderate erythema 
was vis ible after 48 and 72 hat sites tested with PDC-liposomes 
on all sensitized animals. Empty liposomes did not induce a 
dermatitis on sensitized animals. Therefore, PDC in liposomes 
retained the capacity of eliciting allergic contact dermatitis. 
The next experiment was done to determine whether i. e. 
PDC-liposomes sensitize na ive guinea pigs. PDC-liposomes 
were given i.e. to 14 naive animals. The experiment was con-
trolled by injecting empty liposomes i.e. into 7 naive animals. 
Two weeks later 7 PDC-liposome-treated and 7 empty lipo-
some-treated animals received PDC elicitation patches, empty 
liposome patches, and PDC-liposome patches. The remaining 
7 PDC-liposome-treated animals were patch tested 3 weeks 
(instead of2 weeks) after i.e. injection to PDC, empty liposomes, 
a nd PDC-liposomes. 
The resu lts are shown in Fig 3 and indicate that i.e. PDC-
liposomes and empty liposomes do not sensitize naive guinea 
pigs to PDC. Because there was no difference in patch test 
r esults between the i.e. PDC-liposome-treated groups, whether 
tested at 2 or 3 weeks post injection, these results were com -
bined. Empty liposome and PDC-liposome patch tests were 
negative in all animals in both groups (data not shown) . There-
fore , i.e. PDC-li posomes and empty liposomes do not sensit ize 
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FIG 2. Cutaneous reactivity of guinea pigs to DNCB patch tests. 
Cutaneous reactivity of naive vs. DNCB-sensitized guinea pigs to 
DNCB patch tests compared to the cutaneous reactivity of guinea pigs 
treated with i.e. PDC- Iiposomes 1 week prior to the application of a 
sensitizing dose of DNCB; 2 weeks after the sensitizing dose was 
applied, the patch tests were done. 
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F IG 3. Effect of i.e. PDC-Iiposomes or i. e. empty liposomes on the 
cutaneous reactivity of naive guinea pigs to PDC. Two weeks before 
applying PDC elicitation patch tests, naive guinea pigs received either 
i.e. PDC-liposomes or empty liposomes. PDC patch test results on 
naive and PDC-sensitized animals are included for comparison. 
T o determine what effect prior i.e. PDC-liposome treatment 
wou ld have on the capacity to sensit ize with PDC, PDC-lipo-
somes (1 .mg) were given i.e. to 20 a nimals 1 week before t he 
cutaneous application of 250 p.g of PDC (a sensit izing dose). 
The experiment was controlled, with 8 animals receiving empty 
liposomes i.e. a nd 10 animals receiving PDC (1 mg) disso lved in 
50% ethanol i.e. (1 cc total volume) I week before a topical 
sensit izing dose of PDC was applied. Two weeks after topical 
sensit izing closes were applied, elicitation patches were applied. 
Fig 4 shows that PDC-liposomes given i. e. to na ive a nimals 
1 week before attempted PDC topical sensit ization significantly 
inhibi ted sensit ization (p < 0.005). However, empty liposome 
and PDC in etha nol pretreatment did not s ignificant ly inhibi t 
sensit ization (p > 0.05) . PDC-ethanol sligh tly inhibited sensi-
tization, bu t this was not statistically significant (p > 0.05). 
In ord er to investigate the duration of this sensitization 
inhibi tion, 9 animals that showed inhibit ion of sensitization 
after receiving PDC-liposomes 1 week prior to attempted topi-
cal sensit ization were r ested for 2 weeks after t he ini t ial elici-
tation patches and again patch tested to PDC. The experiment 
was controlled wi th 10 naive a nimals which were patch tested 
to PDC, r ested for 2 weeks, a nd again patch tested (data not 
shown). For ty-four percent of the a nimals that had received 
PDC-liposomes 1 week prior to attempted topical PDC sensi-
tization and t hat did not ini t ially show a n allergic contact 
dermatitis exhibi ted a lle rgic contact dermatitis to the second 
series of PDC patch tests. Simila1·Iy, 46% of naive a nimals that 
were patch tested th en patc ~1 tested again 2 weeks later devel-
oped allergic contact derma ti t is to PDC. This indicates that 
patch testing alone is capable of inducing a n allergic contact 
dermatit is a nd, therefore, acts as a sensit izing dose in approxi-
mately 50% of the animals. In addi t ion, the sensit ization inhi-
bition induced by i.e. PDC-liposomes was abolished by t he first 
patch test. 
To further investigate the dLU·ation of the sensitization inhi-
bition , the t ime between the i.e. PDC- liposome dose a nd the 
topical PDC sens it izing dose was increased from 1 week to 2 
and 3 weeks in 2 groups of 6 animals each. The results are 
depicted in Fig 5. When t he t ime interval between the i.e. PDC-
liposome injection and t he application of the sensitizing dose 
was increased ti·om 1 to 2 or 3 weeks, sensitization was no longer 
inhibi ted. These two experiments indicate that inhibition of 
sensit ization by i.e. PDC-liposomes wanes after 1 week and that 
the inhibition, once established, also wanes after 2 weeks be-
cause it is broken by patch testing. 
In order to determine whether the inhibit ion of PDC sensi-
tization by i. e. PDC-liposomes was specific, 10 guinea pigs were 
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F IG 4. Effect of i.e. PDC-liposomes, PDC-ethanol, or empty lipo-
some pretreatment on the production of PDC allergic contact derma-
titis. Intracardiac PDC-liposomes, or i.e. empty liposomes, or i.e. PDC-
ethanol were given I week prior to the cutaneous application of a PDC-
sensitizing dose. Elicitation patch tests were applied 2 weeks after the 
sensitizing do e. PDC patch te t resul ts on PDC-sensitized and naive 
animals are included for comparison. 
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FIG 5. Effect of increasing time between the i.e. PDC-Iiposome dose 
and the topical PDC-sensitizing dose on the cutaneous reactivi ty to 
PDC. Intracardiac PDC-liposomes were given either 1, 2, or 3 weeks 
prior Lo the application of a topical PDC-sensitizing dose. Patch tests 
were applied 2 weeks after the sensitizing dose. PDC patch test results 
on naive and PDC-sensitized animals are included for comparison. 
given a normally sensitizing topical application of DNCB 1 
week after i.e. injection of PDC-liposomes. Two weeks later 
elicitation patch tests to DNCB were appli ed. Pretreatment 
with PDC-liposomes was found not to inhibit t h e development 
and elicitation of allergic contact dermatitis to DNCB (Fig 2). 
To determine what effect t he i.d. administration of PDC-
liposomes would have on 't he cutaneous reactivity to PDC, 
naive guinea pigs were given i.d. PDC-liposomes (1 mg PDC 
total ) divided into 6 injections scattered over t he shaved and 
epilated dorsal neck and back. Three weeks later PDC elicita-
tion patch tests showed an irri tan t contact dermatitis in 5 of 7 
guinea pigs. Only 2 anim als showed evidence of sen sitization 
(data not shown). 
Since th e one-time i.d. injection of 1 mg PDC-liposomes did 
not s how a clear-cu t lack of induction of a llergic contact der-
matitis, 10 other animals rece ived i.d . PDC-liposomes (1 mg 
PDC total) ; 0.1 cc PDC-liposomes (0.1 mg PDC) was given per 
injection. T hree injections were given to th e back of th e neck 
and superior back at one sitting (total 0.3 mg PDC) . Three 
series of injections were given, 1 week apart, for 3 weeks. The 
animals were then allowed to rest for 3 weeks before PDC 
eli citation patches were applied. One a nimal out of 10 showed 
a posit ive patch at 6.25 p.g PDC, and th e other 9 animals h ad 
positive patches only at th e irritant 12.5-p.g patch. Therefor e, 
PDC- liposomes given i.d . do not produce an allergic contact 
dermatitis (data not shown ). 
An additional experiment to determine whether i.d . injected 
PDC-liposomes wou ld inhibi t sensitization revealed that sensi-
tization cou ld not be inhibited by i.d . PDC-liposome injections 
given 1 week before a topically sensitizing dose of PDC (data 
not sh own). 
DISCUSSION 
By incorporating PDC into liposomes we h ave effectively 
suspended PDC in an aqueous solution for presentation to the 
immune system by the tolerogenic i.v. route. One week after 
i.v. PDC-liposome treatment, induction of PDC topical sensi-
t ization was inhibited in guinea pigs. However, 2 weeks after 
PDC-liposome injection, th e sens it ization inhibitory effect had 
waned . In con trast to PDC-liposomes, the hapten given alone 
(PDC in ethanol) did not produce significant sensit ization in-
hibi t ion . Specificity of sensitization inhibition was shown when 
i.e . PDC-liposome pretreatment did not inhibit DNCB sensiti-
zation. 
Three weeks after PDC-liposomes were given i.d. , PDC sen-
sitization was not induced in 90% of the animals; however , 
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unlike i.e. PDC-liposomes, i.d. PDC-liposome injections did not 
inhi bit sensitization to topical PDC when applied 1 week after 
the injections. Intradermal PDC-liposomes may require more 
than 1 week to produce toleran ce . If so, this would parallel 
Bowser and Baer's work which showed the production of tol-
erance and not sensitization 3 weeks after i.d. inj ection of l mg 
PDC in mineral oil [1]. 
S imilar to the studies of Frey, deWeck, Gelleick, et al [12] , 
Claman, Miller, a nd Wetzig [13-17], Aldo-Benson a nd Borle 
[18], a nd with other contact antigens and PDC by Epstein, 
Byers, and Bau [5], we have induced immune tolerance t hat is 
an tigen specific a nd that wanes with t ime. A number of exper-
iments have shown that the induction of tolera nce in contact 
sens it ivi ty models requires time to develop [19]. Indeed, Claman 
showed t hat tolerance to DNFB, DNBS03, a nd DNFB-RBC 
membrane took 5-7 days to develop in mice after i.v. injectio n 
[14]. By 4-8 weeks after i.v. injection, tolerance h ad waned 
[15]. We, therefore, chose to inject PDC-liposomes 1 week prior 
to sensitization in hopes of achieving maximum tolerance pro-
duction. The loss of tolera nce in our system by 2 weeks after 
injection may reflect a dose-dependent phenomenon which will 
r equire more PDC-liposomes to induce prolonged tolerance. In 
humans, Epstein et a! [5] produced sensitization inhibition to 
PDC by 4 i.m. injections of ur ushiol oil (4 mg each). Initial PDC 
patch tests were negative but subsequently were positive when 
patch tested again. A dose response was not investigated. Frey 
eta! [12] showed that there was a clear dose dependence of the 
tolerogenic effect of DNBS0,3; i.e., animals given low doses of 
DNBSOa developed short-lived tolerance that was broken b y 
patch testing, whereas animals given 600 mg/kg of DNBSOa on 
2 occasions developed tolerance that was long-lasting and not 
broken by patch testing. We are currently investigat ing whether 
increasing t he PDC-liposome dose will increase the duration of 
tolerance. 
Because Claman and Miller h ave shown t hat toleran ce to 
DNFB is best produced by i.v. DNFB coupled to cell m embra n e 
rather than by i.v. DNFB alone [15], we chose to incorporate 
PDC into cell membrane models, i.e. , liposom es. Indeed, we 
were able to show that when given in equivalen t amounts, PDC 
incorporated into liposomal membranes is an efficient tolerizer 
compared to PDC injected alone, which was not able to induce 
significant tolerance. Liposomes may, therefore, be a ble to 
function as cell membrane substitutes in the production of 
tolerance. 
Compared to haptenated cell membrane tolerizers, hapten -
ated liposomal membranes are simple and take little time to 
prepare; therefore, they m ay be more practical to use. Since 
liposomal membranes lack Ia region gene products found on 
h a pte nated cell m embranes, this may indicate that Ia antigen 
recogni tion is not n ecessary for T -cell self-recognition and tol-
e rance production, as Claman and Miller speculated [17]. How-
ever, since liposomal membranes have been shown to fu se with 
RES cell membra nes in vivo [7-11], haptenated liposomal 
membra nes given i.v. may produce haptenated RES cell mem-
branes which then mediate tolerance production via Ia antigen 
recognition. Future studies comparing the efficiency of toler-
ance production by haptenated cell vs. liposomal membra nes 
might h elp elucidate the m ech a nism of tolerance production. 
The authors wish to express appreciation to Dr. Hieko Okamura for 
her technical assistance and to Dr. Mike Kutner for his aid in statistical 
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Immunologic Studies of Poisonous Anacardiaceae: Oral Desensitization 
to Poison Ivy and Oak Urushiols in Guinea Pigs 
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Poison ivy and oak urushiols or their components were 
compared with the respective esterified derivatives for 
efficacy in oral desensitization of Hartley guinea pigs 
sensitized to urushiols. The esterified derivatives pro-
duced a significantly greater degree of hyposensitization 
than did free urushiol counterparts. Suppression pro-
duced by esterified urushiols was oflonger duration than 
that produced by free urushiols. Groups of sensitized 
guinea pigs were given high (100 mg/kg) or low (10 mg/ 
kg) doses of a mixture of acetylated, saturated urushiol 
congeners over a 1-, 2-, or 3-week p e riod. High doses 
produced a greater degree of hyposensitization regard-
less of the dosage schedule used. Low doses did not 
produce significant hyposensitization unless given over 
a shorter (1 week) schedule . Large single booster doses 
(33 rug/kg/week) of the acetate derivatives produced a 
rebound in responsiveness when given, 2 weeks follow-
ing the last dose of the initial series, to animals hyposen-
sitized with 10 mg/kg. No such rebound in sensitivity 
occurred in animals given a series of high initial doses. 
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Abbreviations: 
HOC: 3-n-heptadecylcatechol 
MWF: Monday, Wednesday, and Friday 
PDC: 3-n-pentadecylcatechol 
PIU: poison ivy urushiol 
POU: poison oak urushiol 
The dosage and schedule were also shown to be impor-
tant considerations for achieving maximal hyposensiti-
zation. The most important finding of this study was that 
sensitized guinea pigs can b e d esensitized or hyposensi-
tized to poison ivy and oak urushiols via the oral route. 
Antigen therapy has been a popular method used by c]jni-
cians during t his century for a ttempted reduction of the sensi-
tivity of humans to poison ivy, oak, a nd sumac (Rhus) allergens. 
The benefits and safety of the use of Rhus extracts (containing 
the active a llergenic ingredien ts, urushiols) for this pw·pose 
have been topics of dispute since they were first administered 
by physicians in 1917. Several reviews pertaining to th e c)jnical 
use of Rhus extracts and allergens have been written [1-3]. 
From these reviews two salient conclusions emerge. Firstly, 
Rhus extracts should not be used therapeutically, but rather 
prophylactically. Very small amounts of allergen should be 
given initially and extreme caut ion should be used in selecting 
and escalating the dosage, since urushiols a re highly toxic and 
can exacerbate active dermatitis [3]. Secondly, a measure of 
hyposensitization in some cases m ay be achieved but only after 
prolonged administration and after cumulative doses of 2-4 g of 
a nt igen [1). In hypersensit ive subj ects, many mon ths, and in 
so me cases over a year, may be required to achieve measw·able 
hyposensit ization. Adverse reactions to even minute doses of 
a llergen prevent the rapid escalation of doses of Rhus extracts. 
The guinea pig is the accepted animal model for study ing 
Rhus type a llergens since it can be made highly sensitive to 
urus hio.ls a nd the cutaneous reactions ar e similar to those seen 
in sensitive humans [ 4). Susceptibility to sensitization can be 
blocked in guinea pigs by injections of urushiol componen ts 
